Velayos FS - Search Results

1

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. Melmed GY, et al. Among authors: velayos fs. Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451665

2

Risk factors for recurrent emergency care utilization for flares in inflammatory bowel disease.

Hassid BG, Wei J, Sax D, Velayos FS. Hassid BG, et al. Among authors: velayos fs. Acad Emerg Med. 2024 Jan;31(1):28-35. doi: 10.1111/acem.14823. Epub 2023 Nov 5. Acad Emerg Med. 2024. PMID: 37876120 Free article.

3

On a Knife's Edge: Management of Vulvar Cutaneous Crohn's Disease.

Evans NS, Velayos FS. Evans NS, et al. Among authors: velayos fs. Dig Dis Sci. 2023 Apr;68(4):1113-1117. doi: 10.1007/s10620-022-07818-9. Epub 2023 Feb 18. Dig Dis Sci. 2023. PMID: 36808323 No abstract available.

4

Rise over Runs: Elevated Creatinine and a New Diagnosis of Inflammatory Bowel Disease.

Velayos FS. Velayos FS. Dig Dis Sci. 2023 May;68(5):1706-1708. doi: 10.1007/s10620-023-07852-1. Epub 2023 Mar 7. Dig Dis Sci. 2023. PMID: 36881199 No abstract available.

5

AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.

Singh S, Ananthakrishnan AN, Nguyen NH, Cohen BL, Velayos FS, Weiss JM, Sultan S, Siddique SM, Adler J, Chachu KA; AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org. Singh S, et al. Among authors: velayos fs. Gastroenterology. 2023 Mar;164(3):344-372. doi: 10.1053/j.gastro.2022.12.007. Gastroenterology. 2023. PMID: 36822736

6

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease.

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. Laine L, et al. Gastrointest Endosc. 2015 Mar;81(3):489-501.e26. doi: 10.1016/j.gie.2014.12.009. Gastrointest Endosc. 2015. PMID: 25708752 No abstract available.

7

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.

Smith JT, Velayos FS, Niu F, Liu V, Delate T, Pola S, Le K, Hui RL. Smith JT, et al. Among authors: velayos fs. Crohns Colitis 360. 2021 Jul 29;3(3):otab051. doi: 10.1093/crocol/otab051. eCollection 2021 Jul. Crohns Colitis 360. 2021. PMID: 36776661 Free PMC article.

8

A Response-able Diagnosis: Type 2 Autoimmune Pancreatitis in the Setting of Ulcerative Colitis.

Kane K, Velayos FS, Lee JK, Cherny S, Karia K. Kane K, et al. Among authors: velayos fs. Dig Dis Sci. 2024 Jun;69(6):1934-1938. doi: 10.1007/s10620-024-08408-7. Epub 2024 Apr 18. Dig Dis Sci. 2024. PMID: 38637453 No abstract available.

9

Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?

Velayos FS. Velayos FS. Aliment Pharmacol Ther. 2023 Aug;58(3):361-362. doi: 10.1111/apt.17565. Aliment Pharmacol Ther. 2023. PMID: 37452585 No abstract available.

10

SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease.

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. Laine L, et al. Gastroenterology. 2015 Mar;148(3):639-651.e28. doi: 10.1053/j.gastro.2015.01.031. Gastroenterology. 2015. PMID: 25702852 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters